BMJ  2004;329:1411 (11 December), doi:10.1136/bmj.329.7479.1411

reviews

PERSONAL VIEWS

Pitfalls on the road to drug safety

The first 150 words of the full text of this article appear below.

The recent withdrawal of rofecoxib (Vioxx) from the worldwide market has focused intense public scrutiny on drug safety. Although the US Food and Drug Administration monitors drug safety after product approval, some have raised concerns about whether this system, which relies primarily upon voluntary reporting of adverse drug effects, is adequate to protect the public from unsafe pharmaceuticals.

In his televised appearance before the US Senate finance committee on 18 November, Dr David Graham, associate director in the FDA's Office of Drug Safety, claimed his own agency was "incapable of protecting [the public]" from other dangerous pharmaceuticals ( BMJ 2004;329: 1253[Free Full Text]). He then listed five drugs that he considered potentially unsafe—the acne drug isotretinoin (Roaccutane), the weight loss drug sibutramine (sold as Reductil in Britain and Meridia in the United States), the cyclooxygenase-2 inhibitor valdecoxib (Bextra), the lipid lowering drug rosuvastatin (Crestor), and the asthma . . . [Full text of this article]

Bethesda, Maryland mcschoenberger@aol.com

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Why doctors don't read research papers: Editors' behaviour might have something to do with it

Christopher W Ide
BMJ 2005 330: 256. [Extract] [Full Text]

Why doctors don't read research papers: Scientific papers are not written to disseminate information

Michael O'Donnell
BMJ 2005 330: 256. [Extract] [Full Text]